Cordarone

• Vasodilator Agents
• Enzyme Inhibitors
• Anti-Arrhythmia Agents
• ATC:C01BD01

• Aminodarone
• Amiodarona
• Amiodarona [INN-Spanish]
• Amiodarone Base
• Amiodarone HCL
• Amiodarone Hydrochloride
• Amiodarone [USAN:BAN:INN]
• Amiodarons
• Amiodaronum [INN-Latin]
• Amjodaronum
• Cordarone
• Cordarone I've.
• Cordarone Intravenous
• Labaz
• Pacerone
• Uro-Septra
• pms-Amiodarone

• No information avaliable

C₂₅H₂₉I₂NO₃

http://www.rxlist.com/cgi/generic/amiodarone.htm

Cordarone FDA

Cordarone MSDS

No information avaliable

645.312 g/mol

No information avaliable

Low

Solid

7.706

Liquid; Solution; Tablet (200 mg and 400 mg)

Intravenously, for initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia in patients refractory to other therapy. Orally, for the treatment of life-threatening recurrent ventricular arrhythmias such as recurrent ventricular fibrillation and recurrent hemodynamically unstable ventricular tachycardia.

Amiodarone belongs to a class of drugs called Vaughan-Williams Class III antiarrhythmic agents. It is used in the treatment of a wide range of cardiac tachyarhthmias, including both ventricular and supraventricular (atrial) arrhythmias. After intravenous administration in man, amiodarone relaxes vascular smooth muscle, reduces peripheral vascular resistance (afterload), and slightly increases cardiac index. Amiodarone prolongs phase 3 of the cardiac action potential. It has numerous other effects however, including actions that are similar to those of antiarrhythmic classes Ia, II, and IV. Amiodarone shows beta blocker-like and calcium channel blocker-like actions on the SA and AV nodes, increases the refractory period via sodium- and potassium-channel effects, and slows intra-cardiac conduction of the cardiac action potential, via sodium-channel effects.

Slow and variable (about 20 to 55% of an oral dose is absorbed).

Intravenous, mouse: LD₅₀ = 178 mg/kg. Some side effects have a significant mortality rate: specifically, hepatitis, exacerbation of asthma and congestive failure, and pneumonitis.

No information avaliable

Humans and other mammals